172 related articles for article (PubMed ID: 2559394)
1. Angiotensin-converting enzyme inhibitors: mechanistic controversies.
Ujhelyi MR; Ferguson RK; Vlasses PH
Pharmacotherapy; 1989; 9(6):351-62. PubMed ID: 2559394
[TBL] [Abstract][Full Text] [Related]
2. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity.
Zusman RM
Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):13-23. PubMed ID: 3037886
[TBL] [Abstract][Full Text] [Related]
3. The role of tissue renin-angiotensin systems in hypertension and effects of chronic converting-enzyme inhibition.
Keuneke C; Yacullo R; Metzger R; Hellmann T; Peters J; Ganten D
Eur Heart J; 1990 May; 11 Suppl D():11-6. PubMed ID: 2163328
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.
Van Zwieten PA; De Jonge A; Timmermans PB
Pharm Weekbl Sci; 1983 Oct; 5(5):197-204. PubMed ID: 6316248
[TBL] [Abstract][Full Text] [Related]
5. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril.
Atlas SA; Case DB; Yu ZY; Laragh JH
Am J Med; 1984 Aug; 77(2A):13-7. PubMed ID: 6089554
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic converting enzyme inhibition on the vascular renin-angiotensin system.
Saito H; Nakamaru M; Rakugi H; Mikami H; Ogihara T; Inagami T
Clin Exp Pharmacol Physiol; 1990 Nov; 17(11):745-53. PubMed ID: 2150362
[TBL] [Abstract][Full Text] [Related]
7. In vivo inhibition of nitric oxide synthesis does not depend on renin-angiotensin system activation.
Zappellini A; Teixeira SA; Muscará MN; Zatz R; Antunes E; De Nucci G
Eur J Pharmacol; 1996 Dec; 317(2-3):285-91. PubMed ID: 8997612
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme inhibitors suppress the vascular renin-angiotensin system of spontaneously hypertensive rats.
Higashimori K; Nakamaru M; Tabuchi Y; Nagano M; Mikami H; Ogihara T; Inagami T
Am J Hypertens; 1991 Jan; 4(1 Pt 2):56S-59S. PubMed ID: 2009150
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition.
Kiowski W; Linder L; Kleinbloesem C; van Brummelen P; Bühler FR
Circulation; 1992 Jan; 85(1):1-8. PubMed ID: 1728438
[TBL] [Abstract][Full Text] [Related]
10. [Angiotensin converting enzyme inhibitory activity of MK-0521 in vivo and antihypertensive effect of its single oral administration on blood pressure and effect on the renin-angiotensin system in 2-kidney Goldblatt hypertensive dogs].
Oda M; Ino Y; Suzuki K; Sato T; Iwamoto S; Iwaki M
Nihon Yakurigaku Zasshi; 1989 Apr; 93(4):225-34. PubMed ID: 2545579
[TBL] [Abstract][Full Text] [Related]
11. The effects of converting enzyme inhibitors on plasma angiotensinogen and plasma aldosterone in sodium-depleted rats.
Clauser E; Gonzalez MF; Bouhnik J; Corvol P; Ménard J
J Hypertens Suppl; 1983 Oct; 1(1):37-40. PubMed ID: 6100608
[TBL] [Abstract][Full Text] [Related]
12. Unrelated responses of brachial artery hemodynamics and renin-angiotensin system to acute converting enzyme inhibition by enalaprilat in essential hypertension.
Levenson J; Chau NP; Billaud E; Simon A
Am J Cardiol; 1988 May; 61(13):1056-60. PubMed ID: 2834938
[TBL] [Abstract][Full Text] [Related]
13. Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers.
Shepherd AN; Campbell BC; Reid JL
J Cardiovasc Pharmacol; 1982; 4(3):381-7. PubMed ID: 6177933
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril.
Levine TB; Olivari MT; Cohn JN
Am J Med; 1986 Oct; 81(4C):36-9. PubMed ID: 3022583
[TBL] [Abstract][Full Text] [Related]
15. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors.
Unger T; Gohlke P
Am J Cardiol; 1990 May; 65(19):3I-10I. PubMed ID: 2159693
[TBL] [Abstract][Full Text] [Related]
16. Effect of converting enzyme inhibitors on tissue converting enzyme and angiotensin II: therapeutic implications.
Unger T; Ganten D; Lang RE
Am J Cardiol; 1987 Apr; 59(10):18D-22D. PubMed ID: 3034027
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
Laubie M; Schiavi P; Vincent M; Schmitt H
J Cardiovasc Pharmacol; 1984; 6(6):1076-82. PubMed ID: 6084763
[TBL] [Abstract][Full Text] [Related]
18. The tissue renin-angiotensin system: a target for angiotensin-converting enzyme inhibitors.
Ganten D; Mullins J; Lindpaintner K
J Hum Hypertens; 1989 Jun; 3 Suppl 1():63-70. PubMed ID: 2674443
[TBL] [Abstract][Full Text] [Related]
19. Circulatory and extracirculatory effects of angiotensin-converting enzyme inhibition.
Weber MA; Neutel JM; Smith DH
Am Heart J; 1992 May; 123(5):1414-20. PubMed ID: 1575168
[TBL] [Abstract][Full Text] [Related]
20. Effect of alacepril on renin-angiotensin-aldosterone system and kallikrein-kinin-prostaglandin system in experimental animals.
Hosoki K; Takeyama K; Minato H; Fukuya F; Kawahara S; Kadokawa T
Arzneimittelforschung; 1986; 36(1):77-83. PubMed ID: 3006712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
